Progressive Multifocal Leukoencephalopathy (PML)

Progressive Multifocal Leukoencephalopathy (PML)

Introduction

Progressive Multifocal Leukoencephalopathy (Pml) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@zhai2018]

Overview

Progressive multifocal leukoencephalopathy (PML) is a severe, often fatal demyelinating disease of the central nervous system caused by reactivation of the JC polyomavirus (JCPyV) in immunocompromised individuals. JCPyV, named after the initials of the patient from whom it was first isolated in 1971, is a ubiquitous human pathogen that establishes lifelong latent infection in approximately 50–80% of the adult population but only causes disease when cellular immunity — particularly CD4+ T-cell function — is severely impaired . [@zhai2018] [@berger2014]

PML is characterized by progressive, multifocal areas of white matter destruction resulting from lytic infection and destruction of [oligodendrocytes](/cell-types/oligodendrocytes) by JCPyV. The disease was first described pathologically by Åström, Mancall, and Richardson in 1958 in patients with lymphoproliferative disorders. Prior to the HIV/AIDS epidemic, PML was exceedingly rare; the emergence of AIDS dramatically increased its incidence, and more recently, the use of immunosuppressive monoclonal antibodies (particularly natalizumab for multiple sclerosis) has created a new at-risk population. [@berger2014] [@weiner1974]

Progressive Multifocal Leukoencephalopathy (PML)

Introduction

Progressive Multifocal Leukoencephalopathy (Pml) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@zhai2018]

Overview

Progressive multifocal leukoencephalopathy (PML) is a severe, often fatal demyelinating disease of the central nervous system caused by reactivation of the JC polyomavirus (JCPyV) in immunocompromised individuals. JCPyV, named after the initials of the patient from whom it was first isolated in 1971, is a ubiquitous human pathogen that establishes lifelong latent infection in approximately 50–80% of the adult population but only causes disease when cellular immunity — particularly CD4+ T-cell function — is severely impaired . [@zhai2018] [@berger2014]

PML is characterized by progressive, multifocal areas of white matter destruction resulting from lytic infection and destruction of [oligodendrocytes](/cell-types/oligodendrocytes) by JCPyV. The disease was first described pathologically by Åström, Mancall, and Richardson in 1958 in patients with lymphoproliferative disorders. Prior to the HIV/AIDS epidemic, PML was exceedingly rare; the emergence of AIDS dramatically increased its incidence, and more recently, the use of immunosuppressive monoclonal antibodies (particularly natalizumab for multiple sclerosis) has created a new at-risk population. [@berger2014] [@weiner1974]

Without immune reconstitution, PML is almost uniformly fatal within months. There is no specific antiviral therapy, and the primary treatment strategy involves restoring immune function, which itself carries the risk of immune reconstitution inflammatory syndrome (IRIS) . [@breville2021]

Epidemiology

Prevalence of JC Virus Infection

• JCPyV seroprevalence increases with age: approximately 50% by age 20, 60–70% by age 50, and up to 80% in elderly populations
• Primary infection is typically asymptomatic, occurring in childhood or adolescence
• The virus establishes latency primarily in the kidneys, bone marrow, and possibly the brain
• Viral shedding in urine occurs intermittently in 20–30% of immunocompetent individuals

PML Incidence

• Pre-AIDS era: Extremely rare, with fewer than 200 cases reported in the medical literature by 1984
• AIDS epidemic: PML became the third most common opportunistic CNS infection in AIDS patients, occurring in 3–7% of untreated HIV-positive individuals. At its peak, PML incidence in AIDS patients was approximately 1 per 200 person-years
• Antiretroviral therapy (ART) era: Combined ART has reduced PML incidence in HIV patients by approximately 50–60%, though it remains a significant complication
• Drug-associated PML: The natalizumab era (post-2005) brought renewed attention to PML risk in iatrogenic immunosuppression

Risk Factors

• Natalizumab (Tysabri): Used for MS; estimated PML risk of ~1.5 per 1,000 users, rising to ~11 per 1,000 in JCPyV antibody-positive patients treated >24 months with prior immunosuppressant use
• Rituximab: Anti-CD20 antibody used in lymphoma, rheumatoid arthritis, and MS
• Efalizumab (withdrawn from market due to PML cases)
• Dimethyl fumarate and other MS disease-modifying therapies

Virology

JC Polyomavirus (JCPyV)

JCPyV is a small (40 nm), non-enveloped, double-stranded DNA virus belonging to the family Polyomaviridae. Its genome (~5,100 base pairs) is organized into three functional regions : [@berger2005]

• Early region: Encodes large T antigen (T-Ag) and small t antigen — regulatory proteins essential for viral DNA replication and host cell cycle manipulation
• Late region: Encodes the structural capsid proteins VP1, VP2, and VP3, and the regulatory agnoprotein
• Non-coding control region (NCCR): Contains the origin of replication and promoter/enhancer elements; rearrangements in this region are critical for neurotropism and PML pathogenesis

Neurotropism and Pathogenic Variants

Archetype JCPyV (found in urine of healthy individuals) has a stable, orderly NCCR. In PML, the virus undergoes NCCR rearrangements (deletions, duplications, insertions) that alter transcription factor binding sites and enhance viral replication in [oligodendrocytes](/cell-types/oligodendrocytes) and [astrocytes](/cell-types/astrocytes). These rearranged "PML-type" variants are not found in healthy carriers and appear to arise through quasi-species evolution during immunosuppression . [@henderson2002]

JCPyV enters cells via binding to sialic acid residues (particularly the lactoseries tetrasaccharide c receptor, LSTc) on the cell surface, followed by interaction with 5-HT2A serotonin receptors. Entry is primarily into [oligodendrocytes](/cell-types/oligodendrocytes), which are the main target cells in PML. [@mhn2022]

Pathogenesis

Viral Reactivation

Oligodendrocyte Destruction

• Lytic viral replication within oligodendrocyte nuclei
• Cell death and loss of the myelin sheath these cells maintain
• Progressive, multifocal areas of [demyelination](/mechanisms/demyelination)
• Each focus of demyelination represents independent sites of viral spread

Astrocyte Infection

• Bizarre, enlarged nuclei with "ground-glass" or granular inclusions
• Multinucleated giant [astrocytes](/cell-types/astrocytes)
• Astrocytic infection may facilitate viral spread and contribute to tissue destruction

Immune Response

• In immunocompetent individuals, JCPyV-specific CD4+ and CD8+ T cells control viral replication
• Loss of this surveillance, particularly JCPyV-specific CD8+ cytotoxic T lymphocytes, is the critical permissive factor for PML development
• Upon immune reconstitution (e.g., with antiretroviral therapy or natalizumab withdrawal), the recovering immune response can paradoxically worsen damage through IRIS

Clinical Presentation

Symptoms and Signs

• Motor deficits (present in ~65%): Hemiparesis or monoparesis, clumsiness, gait ataxia
• Cognitive impairment (~45%): Confusion, personality changes, dementia
• Visual deficits (~35%): Homonymous hemianopia, cortical blindness (from parieto-occipital lesions)
• Speech and language (~25%): Aphasia, dysarthria
• Seizures (~15–20%): Can be presenting feature
• Coordination deficits: Ataxia, limb dysmetria (when cerebellar involvement occurs)

JCPyV-Related Disease Spectrum

• JCPyV granule cell neuronopathy (JCV-GCN): Productive infection of cerebellar granule cell [neurons](/entities/neurons), causing progressive cerebellar ataxia with cerebellar atrophy
• JCPyV encephalopathy: Cortical and gray matter involvement with seizures and encephalopathy
• JCPyV meningitis: Isolated meningeal infection without parenchymal involvement

Immune Reconstitution Inflammatory Syndrome (PML-IRIS)

• New or enlarging lesions with contrast enhancement (indicating inflammation)
• Clinical deterioration despite decreasing viral load
• Histopathology shows perivascular lymphocytic infiltration
• Occurs in 15–30% of HIV-PML patients starting ART and in ~75% of natalizumab-associated PML cases
• Can be fatal if severe; management may require corticosteroids to temper the inflammatory response

Neuroimaging

MRI Findings

MRI is the primary imaging modality for PML diagnosis:

• T2/FLAIR: Multifocal, bilateral (but often asymmetric) areas of high signal intensity in the white matter. Lesions typically involve the subcortical U-fibers (distinguishing PML from many other white matter diseases)
• T1: Corresponding hypointense lesions; T1 hypointensity increases over time, reflecting progressive tissue destruction
• Diffusion-weighted imaging (DWI): Active lesion edges show restricted diffusion, indicating active [demyelination](/mechanisms/demyelination) and cytotoxic edema
• Contrast enhancement: Classic PML shows minimal or no gadolinium enhancement (unlike MS lesions). Enhancement, when present, may indicate IRIS or an atypical inflammatory PML variant
• Distribution: Parieto-occipital white matter is most commonly affected, followed by frontal white matter; posterior fossa involvement occurs in ~10–15% of cases

Differential Diagnosis on Imaging

• [multiple sclerosis](/diseases/multiple-sclerosis): Typically periventricular with enhancing lesions; spares U-fibers
• [ALSP](/diseases/alsp): Symmetric frontal white matter changes with calcifications
• [HIV encephalopathy]: Diffuse, symmetric white matter changes
• CNS lymphoma: Mass effect and enhancement
• [CADASIL](/diseases/cadasil)/[CARASIL](/diseases/carasil): Subcortical lacunar infarcts pattern

Diagnosis

Diagnostic Criteria

The diagnosis of PML is established by combining:

• CSF JCPyV PCR has a sensitivity of ~75–90% and specificity >95%
• Quantitative PCR allows monitoring of viral load over time
• False-negative results can occur early in disease or with low viral loads

Biomarkers

• CSF JCPyV DNA: Quantitative viral load correlates with prognosis; decreasing load suggests immune control
• JCPyV antibody index (serum): Used for risk stratification in natalizumab-treated MS patients; index >1.5 indicates higher PML risk
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain ([NfL](/proteins/nfl-protein))): Elevated in PML; may rise before clinical diagnosis, offering potential for early detection.
• CD4+ T-cell count: In HIV patients, PML risk increases dramatically below 200 cells/μL

Treatment

Immune Reconstitution

The cornerstone of PML treatment is restoration of the immune system, as there is no approved antiviral therapy against JCPyV :

• HIV-associated PML: Initiation or optimization of combination antiretroviral therapy (cART). Survival has improved from <10% to approximately 50% with effective ART
• Natalizumab-associated PML: Immediate drug discontinuation. Plasma exchange (PLEX) or immunoadsorption to accelerate natalizumab clearance and restore immune surveillance; ~75% develop IRIS
• Hematological malignancy-associated PML: Reduction or cessation of immunosuppressive therapy where possible
• Transplant-associated PML: Reduction of immunosuppression, balanced against rejection risk

Experimental Antiviral Approaches

No antiviral agent has demonstrated definitive efficacy in controlled trials, but several have shown promise :

• Cidofovir: Nucleotide analog with in vitro activity against JCPyV; clinical trials in PML showed inconsistent results
• Mirtazapine: Blocks 5-HT2A receptors (JCPyV entry receptor); anecdotal benefit but no controlled trial evidence
• Mefloquine: Antimalarial with in vitro anti-JCPyV activity; randomized trial showed no benefit
• Brincidofovir (CMX001): Oral lipid conjugate of cidofovir; early reports encouraging but larger studies inconclusive
• Tenofovir alafenamide fumarate (TAF): Recent (2025) report showing temporal association between TAF initiation and JCPyV clearance in a non-HIV PML case, suggesting potential direct antiviral activity

Immunotherapeutic Strategies

• Immune checkpoint inhibitors: Pembrolizumab (anti-PD-1) has been used off-label in PML patients, with case reports showing clinical stabilization and JCPyV clearance. PD-1 blockade appears to reinvigorate exhausted JCPyV-specific T cells
• Adoptive T-cell transfer: Donor-derived JCPyV-specific T cells have been used experimentally in transplant-associated PML
• IL-7 therapy: Recombinant IL-7 to expand JCPyV-specific T cells under investigation

Management of PML-IRIS

• Corticosteroids (high-dose methylprednisolone) for severe IRIS with mass effect or clinical deterioration
• Monitoring with serial MRI and clinical assessment
• Balance between controlling inflammation and maintaining antiviral immunity

Prognosis

Prognosis depends on the underlying cause of immunosuppression and the degree of immune recovery :

• HIV-associated PML with effective ART: 1-year survival ~50–60%; functional outcomes are variable, with many survivors having significant residual deficits
• Natalizumab-associated PML: Overall mortality ~25%; many survivors have moderate to severe disability
• Hematological malignancy-associated PML: Worst prognosis; 1-year mortality >80% due to limited options for immune reconstitution
• Favorable prognostic factors: Higher CD4+ count at PML diagnosis, low CSF JCPyV viral load, smaller lesion burden on MRI, early immune reconstitution

Neuropathology

Classic PML pathology shows :

• Macroscopic: Multiple, irregularly shaped areas of softened, discolored white matter, predominantly subcortical
• Microscopic: The diagnostic triad consists of:

• [microglial](/cell-types/microglia)
• JCPyV antibody testing before and during natalizumab therapy
• Quantitative JCPyV antibody index monitoring (index >1.5 = higher risk)
• Extended interval dosing (EID) of natalizumab may reduce PML risk compared to standard dosing
• Consider switching to alternative MS therapies in high-risk patients

HIV Prevention

• Early initiation of ART to maintain CD4+ counts above 200 cells/μL
• Ongoing monitoring of CD4+ counts and viral load
• PML prophylaxis with JCPyV-specific interventions remains an unmet need

See Also

• [Astrocytes](/cell-types/astrocytes)
• [Oligodendrocytes](/cell-types/oligodendrocytes)
• [All Diseases

Background

The study of Progressive Multifocal Leukoencephalopathy (Pml) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

Recent advances in Progressive Multifocal Leukoencephalopathy (PML) have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

• Genetic studies: Identification of new genetic risk factors and mechanistic insights
• Biomarker research: Development of diagnostic and prognostic biomarkers
• Therapeutic approaches: Investigation of novel treatment strategies
• Clinical trials: Ongoing Phase I-III trials for new therapies

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References